Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study

Lignende værker

• Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
  af: Tanaka, Yoshiya, et al.
  Udgivet: (2020)
• Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis
  af: Takeuchi, Tsutomu, et al.
  Udgivet: (2016)
• The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression
  af: Atsumi, Tatsuya, et al.
  Udgivet: (2016)
• Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
  af: Atsumi, Tatsuya, et al.
  Udgivet: (2017)
• Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
  af: Tanaka, Yoshiya, et al.
  Udgivet: (2016)